Cogstate developed a digital cognitive assessment that revolutionized the early detection of mild cognitive impairment in clinical research. By 2021, the time had come to go beyond clinical trials.
New treatments to slow the progression of Alzheimer's disease were emerging, but their efficacy depends on early detection. Yet 90% of people with mild cognitive impairment (an early indication of Alzheimer’s disease) go undiagnosed. [Source]
To close this gap, Cogstate partnered with Public Works to reimagine Cognigram—a HIPAA-compliant, FDA Class II-exempt digital cognitive assessment proven effective in more than 2,000 clinical trials.
Our goal was to transform the customer experience (CX) for Cognigram’s adoption in doctors’ offices and homes across the U.S.
